You are leaving Smmttx.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible
for its contents.

Summit Therapeutics, Inc., is not responsible for the privacy notice of any third-party websites. We encourage you to read the privacy notice of every website you visit.

To stay on Summit’s website, click “Cancel” or click “Continue” to proceed.

SMT19969 For Clostridium Difficile Infection: Phase 1 Study Investigating Safety And Pharmacokinetics Of Single And Multiple Oral Escalating Doses In Healthy Male Subjects

SMT19969 For Clostridium Difficile Infection: Phase 1 Study Investigating Safety And Pharmacokinetics Of Single And Multiple Oral Escalating Doses In Healthy Male Subjects